Release Advantages of A Liposomal Dendrimer-Doxorubicin Complex, Over Conventional Liposomal Formulation of Doxorubicin

2007 ◽  
pp. 135-144 ◽  
Author(s):  
Aristarchos Papagiannaros ◽  
Costas Demetzos
Keyword(s):  
Liposomal Formulation

scholarly journals In silico screening of drug candidates for thermoresponsive liposome formulations

2021 ◽  
Author(s):  
Martin Balouch ◽  
Martin Šrejber ◽  
Marek Šoltys ◽  
Petra Janská ◽  
František Štěpánek ◽  
...  
Keyword(s):  
In Silico ◽  
Liposomal Formulation ◽  
In Silico Screening ◽  
Drug Candidates

In silico methodology for compound suitability for liposomal formulation has been developed. Water–lipid partitioning and permeation of candidate compounds from the DrugBank were calculated, and the most appropriate targets validated experimentally.

A Transferrin Receptor-Targeted Liposomal Formulation for Docetaxel

2010 ◽  
Vol 10 (8) ◽  
pp. 5129-5136 ◽  
Author(s):  
Guangxi Zhai ◽  
Jun Wu ◽  
Bo Yu ◽  
Chenyu Guo ◽  
Xingguo Yang ◽  
...  
Keyword(s):  
Transferrin Receptor ◽  
Liposomal Formulation

scholarly journals Caprylate-Conjugated Cisplatin for the Development of Novel Liposomal Formulation

2014 ◽  
Vol 15 (4) ◽  
pp. 845-857 ◽  
Author(s):  
Imran Vhora ◽  
Nirav Khatri ◽  
Jagruti Desai ◽  
Hetal Paresh Thakkar
Keyword(s):  
Liposomal Formulation

scholarly journals Flavonoids of Salvadora persica L. (meswak) and its liposomal formulation as a potential inhibitor of SARS-CoV-2

RSC Advances ◽  
2021 ◽  
Vol 11 (22) ◽  
pp. 13537-13544
Author(s):  
Asmaa I. Owis ◽  
Marwa S. El-Hawary ◽  
Dalia El Amir ◽  
Hesham Refaat ◽  
Eman Alaaeldin ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Liposomal Formulation ◽  
Salvadora Persica ◽  
Potential Inhibitor

Several studies are now underway as a worldwide response for the containment of the COVID-19 outbreak; unfortunately, none of them have resulted in an effective treatment.

scholarly journals Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.

1994 ◽  
Vol 38 (4) ◽  
pp. 713-718 ◽  
Author(s):  
J W Lee ◽  
M A Amantea ◽  
P A Francis ◽  
E E Navarro ◽  
J Bacher ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Liposomal Formulation

Development of intravaginal rod insert bearing liposomal raloxifene hydrochloride and Leuprolide acetate as a potential carrier for uterine targeting

2021 ◽  
Author(s):  
Arpita Patel ◽  
Rahul Dhande ◽  
Hetal Thakkar
Keyword(s):  
Entrapment Efficiency ◽  
Leuprolide Acetate ◽  
Liposomal Formulation ◽  
Molar Ratio ◽  
White Female ◽  
Transmission Electron ◽  
Freeze Dried ◽  
Intravaginal Administration ◽  
Raloxifene Hydrochloride ◽  
Dual Drug

Abstract Objectives This project aimed at the formulation of dual drug entrapped liposomes held as freeze-dried intravaginal rod insert (IVR), to be administered by vaginal route for uterine targeting. Methods Liposomes were formulated by dehydration–rehydration method using 3 : 1 molar ratio of1,2-distearoyl-sn-glycero-3-phosphocholine : Cholesterol. Characterization was done for vesicle size, zeta potential, entrapment efficiency, surface morphology and % loading. Key findings Spherical and discrete vesicles of size 354 nm were observed in transmission electron microscopy (TEM) image. The entrapment efficiency of 90.91% and 74.3% w/w was obtained for Raloxifene Hydrochloride (RLX) and Leuprolide acetate (LA) respectively. Drug release was sustained for 6 days. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay results showed that dual drug entrapped liposomal formulation show significant cytotoxicity, as also confirmed by higher apoptosis in cell cycle analysis and apoptosis studies (FACS) analysis. Pharmacodynamic studies in New Zealand white female rabbits revealed that intravaginal administration of RLX-LA entrapped liposomal formulation shows considerable fibroid regression. Conclusions Uterine targeting of liposomal RLX-LA suggests its potential to solve the limitations of the presently available therapeutic options.

scholarly journals Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma [Corrigendum]

2017 ◽  
Vol Volume 12 ◽  
pp. 5119-5120
Author(s):  
Anna Alekseeva ◽  
Ekaterina Moiseeva ◽  
Natalia Onishchenko ◽  
Ivan Boldyrev ◽  
Alexander Singin ◽  
...  
Keyword(s):  
T Cell ◽  
Tumor Cells ◽  
Liposomal Formulation ◽  
Lipophilic Prodrug

Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation

2006 ◽  
Vol 14 (9) ◽  
pp. 652-661 ◽  
Author(s):  
Antonio Di Stefano ◽  
Piera Sozio ◽  
Antonio Iannitelli ◽  
Carlotta Marianecci ◽  
Eleonora Santucci ◽  
...  
Keyword(s):  
Liposomal Formulation

Liposomal Formulation of Retinoids Designed for Enzyme Triggered Release

2010 ◽  
Vol 53 (9) ◽  
pp. 3782-3792 ◽  
Author(s):  
Palle J. Pedersen ◽  
Sidsel K. Adolph ◽  
Arun K. Subramanian ◽  
Ahmad Arouri ◽  
Thomas L. Andresen ◽  
...  
Keyword(s):  
Liposomal Formulation ◽  
Triggered Release
Sign in / Sign up

Export Citation Format

Share Document